Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 3/20 | 0.41 |
| ▸ | GABRD | O14764 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.41 |
| ▸ | GABRE | P78334 | 3/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8539508 | 0.99 | KIF11 (0.51) | KIF11ALDH1A1KDM4EAHRGABRP | |
| Hydrochloric Acid SCHEMBL6049789 | 0.97 | KIF11 (0.50) | KIF11ALDH1A1KDM4EAHRGABRP | |
| SCHEMBL8540782 | 0.91 | ALDH1A1 (0.44) | KIF11ALDH1A1AHRGABRPGABRD | |
| SCHEMBL8542457 | 0.87 | KIF11 (0.51) | KIF11ALDH1A1KDM4EAHRGABRP | |
| SCHEMBL26658373 | 0.75 | KIF11 (0.66) | KIF11ALDH1A1KDM4EAHRGABRP | |
| SCHEMBL2103758 | 0.74 | BACE1 (0.47) | — | |
| SCHEMBL649075 | 0.72 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL8545006 | 0.72 | KDM1A (0.42) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29406954 | 0.71 | HRH3 (0.55) | KIF11ALDH1A1KDM4E | |
| SCHEMBL2102562 | 0.70 | HRH3 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820989-A1 | IMIDAZOLE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-01-28 | — | — | EP | claimed |
| US-11478471-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | STRONGBRIDGE DUBLIN LIMITED (IE) | 2022-10-25 | — | — | US | disclosed |
| US-10835530-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | STRONGBRIDGE DUBLIN LIMITED (IE) | 2020-11-17 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| EP-1853266-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS | Cortendo Invest AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006072881-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS | CORTENDO INVEST AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | disclosed |
| CN-1346282-A | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia | SEARLE & CO (US) | 2002-04-24 | — | — | CN | disclosed |
| EP-0820989-A1 | IMIDAZOLE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835530-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | CYP11B2, HSD3B2, HSD3B1 | KIF11 857/4885ALDH1A1 1953/4885KDM4E 1553/4885 |
| US-11478471-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | CYP11B2, HSD3B2, HSD3B1 | KIF11 1041/4885ALDH1A1 1935/4885KDM4E 1632/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | KIF11 3586/4885ALDH1A1 68/4885KDM4E 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.